Table 2 Preclinical antibody–drug conjugates active in animal models of lymphoma
From: Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Agent | Target | Linker | Payload | Indication |
|---|---|---|---|---|
huB4-DGN462 | CD19 | Sulfo-SPDB | DGN462 | B cell lymphoma [150] |
RC58-based ADC | CD19 | Maleimide-PEG-based linkers | / | B cell lymphoma [151] |
Anti-CD30-LDM | CD30 | Non-cleavable linker | LDM | HL and ALCL [110] |
CD38-077 | CD38 | Non-polyethylene glycol linker | Duostatin 5.2 | Burkitt's lymphoma and MM [152] |
BAY-943 (IL3RA-ADC) | CD123 | Protease-cleavable linker | KSP inhibitor | AML and HL [153] |
BAY 924 | CD185 | / | KSP inhibitor | B cell lymphoma [154] |
MEN1309/OBT076 | CD205 | SPDB | DM4 | B cell lymphoma [155] |
IMMU-140 | HLA-DR | Cleavable linker | SN-38 | HL, NHL and CLL [156] |